- Kidney Failure Risk Equation, Clinical Outcomes, and Effect of Finerenone in HFmrEF/HFpEF: Insights from FINEARTS-HF
-
MDP1764
Brian ClaggettPhDBrigham and Women's Hospital;Brigham and Women's Hospital, Harvard Medical SchoolRyohei Ono, Kieran Docherty, Alasdair David Henderson, Univ of Glasgow, Glasgow, United Kingdom; Brian Claggett, Brigham and Women's Hosp, Boston, MA; Akshay S Desai, Brigham Womens Hosp, Boston, MA; Carolyn SP Lam, Natl Heart Ctr Singapore, Singapore, Singapore; MICHELE SENNI, Asst Papa Giovanni XXIII, Bergamo, Italy; Morten Schou, Herlev Hosp, Herlev, Denmark; Adriaan A Voors, Univ Medical Ctr Groningen, Gronien, Netherlands; Lucas Hofmeister, Bayer AG, Berlin, Germany; Meike Brinker, Bayer AG, Duesseldorf, Germany; Patrick Schloemer, Bayer AG, Berlin, Germany; Faiez ZANNAD, CVCT and Univ de Lorraine, Paris, France; Muthiah Vaduganathan, Brigham and Womens Hosp, Boston, MA; Pardeep S Jhund, Univ of Glasgow, Glasgow, United Kingdom; Scott Solomon, Brigham and Women's Hosp, Boston, MA; John J McMurray, BHF Cardiovascular Res Ctr, Glasgow, United KingdomGeneric 'disconnected' MessageCommunitiesNavigationSession TypeOnsite Viewing
Enter Note
Go to previous page in this tab
Session


